Department of Cardiology, London Chest Hospital, London, UK.
Hellenic J Cardiol. 2013 May-Jun;54(3):159-67.
The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase l-ll trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell-based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing "activity" in numerous published meta-analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the "engineered" cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.
从基础研究到临床应用的快速转化，在再生医学在心脏病学中的应用中已经得到了体现，这使得我们对与人类生物学相关的一些基本机制有了令人兴奋的新认识。在 I 期和 II 期临床试验中使用的第一代细胞（主要是骨髓单核细胞）现在正在进入 III 期临床试验，目标是开发一种基于细胞的治疗方法，可以改变心脏病的结局。第一代细胞治疗似乎已经解决了安全性问题，并在许多已发表的荟萃分析中显示出“疗效”。有了迄今为止获得的知识，该领域正在向新一代细胞——“工程化”细胞迈进，这些细胞被开发出来，以展示出一种表型，从而进一步增强心肌修复/挽救过程。本综述涵盖了最新的基础研究，这些研究可能很快就会应用于人类，以及最新临床试验的结果。
